Adverse Event Considerations in DLBCL

Opinion
Video

Medical oncologists conclude their discussion with a review of the toxicity profiles of treatments for diffuse large B-cell lymphoma.

Recent Videos
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
The Onc Brothers feature one guest in this series.
Related Content
Three patients treated at the first dose level of BAFF CAR-T cells experienced minimal adverse effects in a phase 1 study.

Transposon-Engineered BAFF CAR-T Cells May Elicit Responses in Lymphoma

Roman Fabbricatore
November 13th 2024
Article

Three patients treated at the first dose level of BAFF CAR-T cells experienced minimal adverse effects in a phase 1 study.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Phase 2 data support a favorable risk/benefit profile with valemetostat in patients with relapsed/refractory peripheral T-cell lymphoma.

Valemetostat Yields Enduring Responses in Relapsed/Refractory PTCL

Russ Conroy
November 6th 2024
Article

Phase 2 data support a favorable risk/benefit profile with valemetostat in patients with relapsed/refractory peripheral T-cell lymphoma.

Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.

Epcoritamab Approval Expands Bispecific Use in Follicular Lymphoma

Tycel Phillips, MD
July 8th 2024
Podcast

Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.

The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.

Acalabrutinib Earns FDA Priority Review in Untreated Mantle Cell Lymphoma

Russ Conroy
October 3rd 2024
Article

The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.

Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility

Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility

ONCOLOGY Staff
September 23rd 2024
Article

Nausheen Ahmed, MD, discusses the FDA REMS mandate to help assess toxicity in patients receiving CAR T-cell therapy.